

Nina Radosevic-Robin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3177649/publications.pdf>

Version: 2024-02-01

50
papers

1,990
citations

304743

22
h-index

276875

41
g-index

55
all docs

55
docs citations

55
times ranked

4228
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P1-08-24: Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients. <i>Cancer Research</i> , 2022, 82, P1-08-24-P1-08-24.	0.9	0
2	WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 1487.	3.7	4
3	Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 265-279.	2.5	10
4	Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future".. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 180-181.	0.6	0
5	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. <i>MAbs</i> , 2021, 13, 1914883.	5.2	4
6	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , The, 2021, 22, e18-e28.	10.7	49
7	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 145, 221-229.	2.8	42
8	Prevalence of <i>NTRK1/3</i> fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e15537-e15537.	1.6	2
9	INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 653370.	2.8	2
10	Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 678315.	2.8	17
11	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, 124.	5.2	7
12	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 183-192.	2.2	10
13	STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway. <i>Oncogene</i> , 2021, 40, 6627-6640.	5.9	26
14	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	5.3	75
15	PERCEPTION Trial protocol. <i>Medicine (United States)</i> , 2020, 99, e23418.	1.0	4
16	[¹⁸ F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer. <i>EJNMMI Research</i> , 2020, 10, 2.	2.5	6
17	XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal breast cancer. <i>F1000Research</i> , 2020, 9, 1219.	1.6	2
18	An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. <i>International Journal of Cancer</i> , 2019, 145, 1838-1851.	5.1	33

#	ARTICLE	IF	CITATIONS
19	Sensitive and Specific Detection of Ewing Sarcoma Minimal Residual Disease in Ovarian and Testicular Tissues in an In Vitro Model. <i>Cancers</i> , 2019, 11, 1807.	3.7	4
20	Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. <i>BMC Cancer</i> , 2018, 18, 129.	2.6	40
21	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	9.6	303
22	Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view. <i>Translational Lung Cancer Research</i> , 2018, 7, 716-721.	2.8	10
23	Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma. <i>Medicine (United States)</i> , 2018, 97, e13676.	1.0	28
24	Abstract 5803: Homoharringtonine, a natural protein synthesis inhibitor, inhibits growth of triple negative breast cancer <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Research</i> , 2018, 78, 5803-5803.	0.9	1
25	Ki67 assessment in breast cancer: an update. <i>Pathology</i> , 2017, 49, 166-171.	0.6	157
26	A stemness-related ZEB1–MSRB3 axis governs cellular plasticity and breast cancer genome stability. <i>Nature Medicine</i> , 2017, 23, 568-578.	30.7	131
27	Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. <i>Clinical Cancer Research</i> , 2017, 23, 2806-2816.	7.0	82
28	Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 107-116.	2.4	1
29	Combination of phosphatidylinositol 3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. <i>Head and Neck</i> , 2017, 39, 151-159.	2.0	19
30	Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. <i>Journal of Oncology</i> , 2017, 2017, 1-15.	1.3	171
31	Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer. <i>Laryngoscope</i> , 2016, 126, E156-63.	2.0	24
32	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	5.5	230
33	Stratification and therapeutic potential of PML in metastatic breast cancer. <i>Nature Communications</i> , 2016, 7, 12595.	12.8	45
34	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 487-503.	27.6	43
35	Proliferation Markers in Breast Cancer. , 2016, , 81-98.		0
36	Abstract 1465: Analysis of tumor-infiltrating lymphocytes (TILs) reveals biologically different subgroups of breast ductal carcinoma in situ. , 2016, , .		1

#	ARTICLE	IF	CITATIONS
37	Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. <i>Blood</i> , 2015, 125, 2448-2449.	1.4	28
38	Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 88-104.	4.4	72
39	SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 351-357.	2.5	35
40	Quantification of HER family receptors in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 53.	5.0	39
41	BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e102438.	2.5	54
42	HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. <i>Oncotarget</i> , 2014, 5, 7138-7148.	1.8	43
43	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. <i>Science Signaling</i> , 2014, 7, ra29.	3.6	123
44	Abstract NG01: Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancer. , 2014, , .		0
45	Abstract 1819: Heterogeneity of triple-negative breast cancer response to neoadjuvant treatment: tumor EGFR, HER3 and MET expressions can provide clues for therapy tailoring. , 2014, , .		0
46	Abstract 550: Genomic instability and telomere characteristics as predictive biomarkers of therapeutic response in triple-negative breast cancer. , 2014, , .		0
47	Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC): The immune and IGFR pathways.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1058-1058.	1.6	1
48	Abstract 4669: Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC): the immune and IGFR pathways.. , 2013, , .		0
49	Pathologic complete response (pCR) to predict patients'™ survival in luminal breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11615-e11615.	1.6	0
50	Cetuximab in combination with docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicentre neoadjuvant pilot phase II study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1057-1057.	1.6	0